Search details
1.
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
JAMA
; 2024 May 09.
Article
in English
| MEDLINE | ID: mdl-38722621
2.
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
Br J Cancer
; 124(2): 383-390, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33012782
3.
Discovery of MK-4688: an Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction.
J Med Chem
; 64(21): 16213-16241, 2021 11 11.
Article
in English
| MEDLINE | ID: mdl-34714078
4.
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Clin Cancer Res
; 13(5): 1576-83, 2007 Mar 01.
Article
in English
| MEDLINE | ID: mdl-17332304
5.
Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors.
Clin Cancer Res
; 23(4): 1025-1035, 2017 Feb 15.
Article
in English
| MEDLINE | ID: mdl-28073847
6.
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.
J Med Chem
; 49(2): 441-4, 2006 Jan 26.
Article
in English
| MEDLINE | ID: mdl-16420026
7.
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Mol Cancer Ther
; 15(11): 2563-2574, 2016 11.
Article
in English
| MEDLINE | ID: mdl-27573426
8.
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.
Oncogene
; 22(32): 4953-63, 2003 Aug 07.
Article
in English
| MEDLINE | ID: mdl-12902978
9.
Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy.
Curr Top Med Chem
; 5(2): 215-29, 2005.
Article
in English
| MEDLINE | ID: mdl-15853648
Results
1 -
9
de 9
1
Next >
>>